8-K current report · filed Jul 30, 2026

Tvardi Therapeutics, Inc. (TVRD) 8-K Current Report: July 30, 2026

Item 7.01Item EX-99.1Item EX-99.2TVRD overview

Short answer

Tvardi Therapeutics, Inc. (TVRD) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). TTI-109 selected ulcerative colitis as its initial clinical indication.

Tvardi Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • TTI-109 selected ulcerative colitis as its initial clinical indication
  • Updated corporate presentation provides additional program and company information
  • Ulcerative colitis focus establishes TTI-109’s lead development path and upcoming clinical priorities

Item EX-99.1 · Exhibit EX-99.1

  • TTI-109 selected for ulcerative colitis after Phase 1 healthy-volunteer study, establishing UC as the company’s lead development focus
  • Immune-cell reductions reached 76% for Th17 subsets, 43% for Tfh subsets and 71% for B-cell subsets linked to UC pathology
  • Planned moderate-to-severe UC trial targets 2027, pending IND clearance and additional funding
  • Oral therapy addresses a $3 billion U.S. and $9 billion global UC market with clinical remission rates below 30% for approved therapies
  • Key risks: Phase 1 findings are pharmacodynamic, not efficacy results; development depends on financing and regulatory clearance

Item EX-99.2 · Exhibit EX-99.2

  • July 2026 investor presentation highlights TTI-109, an oral STAT3-inhibitor prodrug advancing toward ulcerative colitis development
  • Phase 1 showed >95% conversion to active TTI-101 within 2 hours and equivalent exposure versus TTI-101 400mg at TTI-109 500mg
  • Repeat dosing produced dose-proportional exposure above the 707ng/mL STAT3 IC50 across 125mg to 500mg BID
  • TTI-109 adverse events were similar to placebo, with no serious events and lower diarrhea burden than TTI-101
  • Healthy-volunteer pharmacodynamics showed reductions up to 60% in STAT3-driven immune populations, supporting planned clinical proof-of-concept testing in ulcerative colitis

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tvardi Therapeutics, Inc. 8-K filings

Get the next TVRD 8-K as it lands

Follow TVRD for push alerts, or ask the research agent what this filing means.